Concomitant oral intake of purified clinoptilolite tuff (G-PUR) reduces enteral lead uptake in healthy humans
Autor: | Michael Wolzt, Claudia Meisslitzer, Cornelius Tschegg, Anastassiya Tchaikovsky, Michael Freissmuth, Anika Retzmann, Johanna Irrgeher, Thomas Prohaska, Karolina Samekova, Christa Firbas, Ghazaleh Gouya, Christine Opper |
---|---|
Rok vydání: | 2021 |
Předmět: |
Adult
Male medicine.medical_specialty Disease prevention Science Therapeutics Urine 010501 environmental sciences Placebo 01 natural sciences Enteral administration Placebo group Gastroenterology Article Double-Blind Method Internal medicine medicine Humans Medical toxicology Lead (electronics) 0105 earth and related environmental sciences Public health Clinoptilolite Multidisciplinary business.industry 010401 analytical chemistry Methods of toxicology studies 0104 chemical sciences Bioavailability Lead Poisoning Lead Concomitant Zeolites Medicine Female business |
Zdroj: | Scientific Reports, Vol 11, Iss 1, Pp 1-8 (2021) Scientific Reports |
ISSN: | 2045-2322 |
Popis: | Lead exposure can cause substantial organ damage. Enteral lead absorption may be reduced by concomitant intake of clinoptilolite tuff, a zeolite from natural sources. This study aimed to assess the effect of purified clinoptilolite tuff (G-PUR) on enteral lead uptake in adults using stable lead isotope 204Pb as a tracer. In this randomized, placebo-controlled, double-blind, parallel-group study, 42 healthy participants were randomized to receive oral G-PUR 2.0 g, 2 * 2.0 g, or placebo, together with 2.5 µg of 204Pb in water. The enrichment of 204Pb caused by the tracer in blood and urine was measured by mass spectrometry. G-PUR was well tolerated. The mean maximum 204Pb enrichment of 0.505% of total blood lead was significantly higher (p 204Pb AUC0-192 was 86.5, 11.9, and 8.5% * h without and with G-PUR 2.0 g, and G-PUR 2 * 2.0 g, respectively (p 204Pb exposure was paralleled by a reduced urinary excretion in subjects receiving G-PUR. Concomitant oral intake of purified clinoptilolite tuff reduced enteral uptake of 204Pb in healthy humans by approximately 90%. The reduced bioavailability is demonstrable by a decrease of 204Pb tracer enrichment in blood and urine.Trial registration: clinicaltrials.gov identifier: NCT04138693, registered 24/10/2019. |
Databáze: | OpenAIRE |
Externí odkaz: |